Author/Authors :
Peter Jüni ، نويسنده , , Linda Nartey، نويسنده , , Stephan Reichenbach، نويسنده , , Rebekka Sterchi، نويسنده , , Paul A Dieppe، نويسنده , , Matthias Egger، نويسنده ,
Abstract :
Background
The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An increased risk of myocardial infarction had been observed in 2000 in the Vioxx Gastrointestinal Outcomes Research study (VIGOR), but
